<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27090">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754063</url>
  </required_header>
  <id_info>
    <org_study_id>38RC14.039</org_study_id>
    <nct_id>NCT02754063</nct_id>
  </id_info>
  <brief_title>Impact of Early Optimization of Brain Oxygenation on the Volume of Cerebral Lesions After Severe Traumatic Brain Injury</brief_title>
  <acronym>OXY-TC</acronym>
  <official_title>Impact of Early Optimization of Brain Oxygenation on the Volume of Cerebral Lesions After Severe Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-traumatic brain hypoxia/ischemia develops hours after traumatic brain injury (TBI), and
      its intensity is directly related to the neurological outcome. The thresholds for
      irreversible tissue damage following TBI indicate a particular vulnerability of injured
      brain. Improving brain oxygenation after severe TBI is the focus of modern TBI management in
      the intensive care unit (ICU).

      The calculation of cerebral perfusion pressure (CPP), with CPP = mean arterial pressure
      (MAP) - intracranial pressure (ICP), has become the most used estimator of cerebral blow
      flow. To prevent ischemia due to elevated ICP, current international guidelines recommend
      maintaining CPP at 60-70 mmHg and ICP below 20 mmHg. However, episodes of brain
      hypoxia/ischemia, as assessed with brain tissue oxygen pressure (PbtO2) measurements, might
      occur despite optimization of CPP and ICP, and have been independently associated with
      poorer patient outcome. PbtO2 values lower than 15 mmHg for more than 30 minutes were shown
      to be an independent predictor of unfavorable outcome and death. The aggressive treatment of
      low PbtO2 was associated with improved outcome compared to standard ICP/CPP-directed therapy
      in cohort studies of severely head-injured patients. On the basis of these findings, it is
      hypothesized that an early optimization of brain oxygenation, together with keeping ICP and
      CPP within recommended values, could reduce the volume of vulnerable lesions following
      severe TBI and possibly improve neurological outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of cerebral lesions with abnormal mean diffusivity values using diffusion tensor imaging</measure>
    <time_frame>6 to 10 days post TBI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extended Glasgow Outcome Scale</measure>
    <time_frame>6 and 12 months post TBI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Independence Measure scale</measure>
    <time_frame>6 and 12 months post TBI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form Health Survey with 12 questions (SF-12)</measure>
    <time_frame>6 and 12 months post TBI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days post TBI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Intensity Level</measure>
    <time_frame>5 days post TBI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of critical neurological events</measure>
    <time_frame>5 days post TBI</time_frame>
    <description>Number of critical events during the first 5 days of the ICU stay as defined by:
ICP &gt;30 mmHg during 30 min at least ICP &gt;40 mmHg during 5 min at least PbtO2 &lt;10 mmHg during 30 min at least (PbtO2 group)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <arm_group>
    <arm_group_label>ICP Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PbtO2 + ICP Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PbtO2 probes</intervention_name>
    <description>PbtO2/ICP/CPP-directed therapy according to international recommendations</description>
    <arm_group_label>PbtO2 + ICP Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No PbtO2 probes</intervention_name>
    <description>ICP/CPP-directed therapy according to international recommendations</description>
    <arm_group_label>ICP Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe non penetrating TBI (initial Glasgow Coma Score 3-8) with motor score between
             1 and 5

          -  Possible associated extracranial lesions, except tetraplegia

          -  Monitoring within the first 16 hours after primary traumatic injury

          -  Indication for ICP monitoring on admission as part of the management

          -  Indication for continuous sedation/analgesia for more than 48 hours

          -  Under mechanical ventilation with stable conditions

          -  Affiliation to the French Social Security or affiliated to a social security system
             of European Union member state, Norway, Lichtenstein, Iceland or Switzerland.

          -  French or English-speaking patient

        Exclusion Criteria:

          -  Penetrating TBI

          -  Glasgow Coma Score 3 with bilateral fixed dilated pupils

          -  Decompressive craniectomy prior to enrolment

          -  Contraindication of ICP and/or PbtO2 monitoring

          -  Persistent hemodynamic or respiratory instability

          -  Hypothermia &lt;34°C at randomization

          -  Venous or arterial lactate concentration &gt;5 mmol/l at randomization

          -  Life expectancy &lt; 24 hours

          -  Cardiac arrest at initial presentation

          -  Tetraplegia

          -  Neuropsychiatric co-morbidities that could interfere with 6 and 12-months evaluation

          -  Consent refusal

          -  Pregnancy

          -  Participation to another study with written consent (but observational and genetics
             study)

          -  Inability to have a 6-months follow-up

          -  Permanent contraindications to MRI

          -  Ischemic stroke after carotid artery dissection

          -  Incapacitated patients in accordance with article L 1121-5 to L1121-8 of the public
             health code.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François PAYEN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pauline MANHES, PhD</last_name>
    <phone>0033476766729</phone>
    <email>pmanhes@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital of Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel GAY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent COTTENCEAU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell CHABANNE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien MIREK, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre BOUZAT, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Kremlin-Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard VIGUE, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel VEGA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric DAILLER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Marseille-Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle HAMMAD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Marseille-Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas BRUDER, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric GRECO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard AUDIBERT, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole ICHAI, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nimes</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélien DAURAT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Paris-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lamine ABDENNOUR, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire DAHYOT-FIZELIER, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoann LAUNEY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène BRAU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of St-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia BURNOL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ambroise MONTCRIOL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas GEERAERTS, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Cunningham AS, Salvador R, Coles JP, Chatfield DA, Bradley PG, Johnston AJ, Steiner LA, Fryer TD, Aigbirhio FI, Smielewski P, Williams GB, Carpenter TA, Gillard JH, Pickard JD, Menon DK. Physiological thresholds for irreversible tissue damage in contusional regions following traumatic brain injury. Brain. 2005 Aug;128(Pt 8):1931-42.</citation>
    <PMID>15888537</PMID>
  </reference>
  <reference>
    <citation>Brain Trauma Foundation.; American Association of Neurological Surgeons.; Congress of Neurological Surgeons.; Joint Section on Neurotrauma and Critical Care, AANS/CNS., Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons SD, Ullman JS, Videtta W, Wilberger JE, Wright DW. Guidelines for the management of severe traumatic brain injury. IX. Cerebral perfusion thresholds. J Neurotrauma. 2007;24 Suppl 1:S59-64. Erratum in: J Neurotrauma. 2008 Mar;25(3):276-8. multiple author names added.</citation>
    <PMID>17511547</PMID>
  </reference>
  <reference>
    <citation>Oddo M, Levine JM, Mackenzie L, Frangos S, Feihl F, Kasner SE, Katsnelson M, Pukenas B, Macmurtrie E, Maloney-Wilensky E, Kofke WA, LeRoux PD. Brain hypoxia is associated with short-term outcome after severe traumatic brain injury independently of intracranial hypertension and low cerebral perfusion pressure. Neurosurgery. 2011 Nov;69(5):1037-45; discussion 1045. doi: 10.1227/NEU.0b013e3182287ca7.</citation>
    <PMID>21673608</PMID>
  </reference>
  <reference>
    <citation>van den Brink WA, van Santbrink H, Steyerberg EW, Avezaat CJ, Suazo JA, Hogesteeger C, Jansen WJ, Kloos LM, Vermeulen J, Maas AI. Brain oxygen tension in severe head injury. Neurosurgery. 2000 Apr;46(4):868-76; discussion 876-8.</citation>
    <PMID>10764260</PMID>
  </reference>
  <reference>
    <citation>Stiefel MF, Spiotta A, Gracias VH, Garuffe AM, Guillamondegui O, Maloney-Wilensky E, Bloom S, Grady MS, LeRoux PD. Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitoring. J Neurosurg. 2005 Nov;103(5):805-11.</citation>
    <PMID>16304983</PMID>
  </reference>
  <reference>
    <citation>Narotam PK, Morrison JF, Nathoo N. Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy. J Neurosurg. 2009 Oct;111(4):672-82. doi: 10.3171/2009.4.JNS081150.</citation>
    <PMID>19463048</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>April 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
